Financial Gravity Asset Management, Inc. Blueprint Medicines Corp Transaction History

Financial Gravity Asset Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$73.17 - $99.79 $292 - $399	4 New	4 $362,000
Q2 2023 Aug 08, 2023	BUY	$42.2 - $66.37 $2,658 - $4,181	63 New	63 $323,000
Q4 2022 Feb 15, 2023	BUY	$41.06 - $66.48 $1,806 - $2,925	44 New	44 $238,000
Q4 2019 Feb 28, 2020	SELL	$66.73 - $82.59 $66 - $82	-1 Closed	0 $0
Q3 2019 Oct 15, 2019	BUY	$72.9 - $101.41 $72 - $101	1 New	1 $0
Q2 2019 Jul 26, 2019	BUY	$73.54 - $97.8 $0 - $0	0 New	0 $0
Q1 2019 Apr 19, 2019	SELL	$48.7 - $86.6 $292 - $519	-6 Closed	0 $0
Q3 2018 Oct 31, 2018	BUY	$58.91 - $78.32 $117 - $156	2 Added 50.0%	6 $0
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $243 - $404	4 New	4 $0

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.